Crossmark

Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men

Crossref DOI link: https://doi.org/10.1016/j.eimce.2024.12.014

Published Print: 2025-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wikman-Jorgensen, Philip Erick

Ruiz-Algueró, Marta

Iniesta, Carlos

Pulido, Federico

Llenas-García, Jara
License Information

Text and Data Mining valid from 2025-08-01

Text and Data Mining valid from 2025-08-01
More Information

This article is maintained by: Elsevier

Article Title: Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men

Journal Title: Enfermedades infecciosas y microbiologia clinica (English ed.)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eimce.2024.12.014

Content Type: article

Copyright: © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Document is current

Any future updates will be listed below